A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Safety and Efficacy of CCX168 (Avacopan) in Patients with Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis Treated Concomitantly with Rituximab or Cyclophospham

Grants and Contracts Details

StatusFinished
Effective start/end date6/19/179/12/19

Funding

  • Medpace Inc: $37,848.00